Humanin
Mitochondria-derived peptide (MDP). Inhibits apoptosis (cell death) induced by Bax and IGFBP-3. Improves insulin action and protects neurons against beta-amyloid toxicity.
- Powerful cytoprotection (cell survival)
- Improved insulin sensitivity
- Neuroprotection (Alzheimer's - models)
- Longevity (correlated with centenarians)Powerful cytoprotection (cell survival)
- Longevity (correlated with centenarians)
- Unknown.
Humanin is a cytoprotective peptide encoded in the mitochondrial genome that plays a crucial role in protection against oxidative stress and in cell survival in multiple tissues.
READ MORE
What it is (in plain language)
- It's a protective shield for your mitochondria (the power plants of cells). Humanine specifically protects neurons and heart cells against programmed death. It is one of the few compounds that acts from the inside of the mitochondria to the outside, preserving cellular energy under stress.
Why do you appear online so much
- It is discussed as a potential therapy for neurodegenerative diseases and type 2 diabetes, due to its ability to improve insulin sensitivity and protect the brain against beta-amyloid plaques.
How it is framed today (pragmatic view)
- 1) Evidence: Growing body of research into mitochondrial biology and longevity. 2) Purpose: Neuroprotection, cardioprotection and metabolic support. 3) Risk: Promising safety profile, but still undergoing in-depth research.
How to use this form
- Check the relationship between Humanina and mitochondrial health in the references database.
- Quick profile (curated by Subject 157)
- Class: Metabolic
- Status: Verified
- Use case: Metabolic
- Route: Injectable
- Tags: Injectable|Longevity|Metabolic
- Half-life: Unknown
- Start: Fast
- Duration: Variable
- Mechanism (high level)
Mitochondria-derived peptide (MDP). Inhibits apoptosis (cell death) induced by Bax and IGFBP-3. Improves insulin action and protects neurons against beta-amyloid toxicity.
- Evidence (what the literature covers)
RANGE OF RESEARCH (Pre-clinical, Non-prescriptive):
Experimental doses in animal models.
Level of Evidence: C (Emerging studies).
- Safety and harm-reduction (non-prescriptive)
Risks: Unknown.
Interactions: Unknown.
- References (anchors)
- Lee, C. (2013) - Humanin as mitochondrial-derived peptide overview - https://doi.org/10.1016/j.tem.2013.01.005 | PubMed:23434231
- Muzumdar, R. H. (2009) - Humanin as central regulator of insulin action - https://doi.org/10.1371/journal.pone.0006334
- Jung, T. W. (2006) - Humanin protects against amyloid-beta - https://doi.org/10.1016/j.bbamem.2006.03.030 | PubMed:16750170
- Matsuoka, M. (2009) - Humanin as a potential therapeutic for AD - https://doi.org/10.1007/s00005-009-0057-2 | PubMed:19838753
Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.
EN 
PT 
FR 
ES 
DE 
IT 
PL